Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant …
Oct 28, 2024 · Merck and Moderna have initiated Phase 3 randomized clinical trials evaluating mRNA-4157 (V940) in combination with KEYTRUDA as an adjuvant treatment in patients with …
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Jun 17, 2024 · KEYTRUDA is now the first and only anti-PD-1 therapy FDA-approved in combination with chemotherapy for adult patients with primary advanced or recurrent …
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Combined …
May 5, 2021 · KEYTRUDA, in combination with chemotherapy, is indicated for the treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) …
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA …
Mar 21, 2024 · KEYLYNK-006 is a randomized, open-label, two-phase Phase 3 trial (ClinicalTrials.gov, NCT03976323) evaluating KEYTRUDA in combination with chemotherapy …
Merck wins first FDA approval for Keytruda as a treatment for ...
Sep 18, 2024 · Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural …
Merck gets a ‘surprise’ win for Keytruda in early lung cancer
Jan 27, 2023 · The Food and Drug Administration has cleared Merck & Co.’s immunotherapy Keytruda to treat early cases of lung cancer despite mixed results in the main study supporting …
Merck's Keytruda extends life for kidney cancer patients after …
Jan 27, 2024 · Merck’s unique approval for Keytruda as a postsurgical treatment for resectable kidney cancer has gained new backing in the form of data showing the PD-1 inhibitor can …
Keytruda is the gift that keeps on giving for Merck, and here’s …
Oct 3, 2022 · Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut. Long-term results showed five-year survival numbers for lung cancer …
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage …
May 28, 2024 · Tuesday, Merck & Co Inc (NYSE:MRK) released topline data from hase 3 KEYNOTE-522 trial of Keytruda in high-risk early-stage triple-negative breast cancer (TNBC).
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus …
Nov 16, 2023 · Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus …
- Some results have been removed